

Partial exercise of the overallotment option

Total size of the offering in connection with the initial public offering increased to a total amount of €25.8m

Bagneux (France) - Genomic Vision (FR0011799907 – GV), a molecular diagnostics company that specializes in the development of diagnostic tests for genetic diseases and cancers using the DNA molecular combing process, today announces that in connection with its initial public offering on the regulated market of Euronext in Paris, Société Générale, acting on behalf of the Joint Lead Managers and Joint Bookrunners, partially exercised the overallotment option allowing the issue of 185,000 new shares at the offering price of €15 per share, corresponding to a total amount of approximately €2.8m.

As a result, the total number of Genomic Vision's shares offered in connection with the initial public offering amounts to 1,718,332 new shares, thereby increasing the offering size to approximately €25.8m.

In accordance, with the provisions of Article 631-10 of the Règlement général of the French Autorité des marchés financiers, Société Générale, acting as stabilizing agent, declares that:

- It has conducted stabilization transactions on Genomic Vision's shares (FR0011799907);
- The stabilization period started on April 2nd, 2014;
- The stabilization period closed on April 9th, 2014;
- Stabilization operations were conducted within the following price range:

Date	Low price	High price
02/04/2014	€15.00	€15.00
03/04/2014	€14.40	€15.00
04/04/2014	€14.46	€14.87
07/04/2014	€14.25	€14.75
08/04/2014	€14.00	€14.45
09/04/2014	€14.00	€14.49

Financial intermediaries



Joint Lead Managers and Joint Bookrunners



Company Advisor

Availability of the prospectus – Copies of the prospectus, which received a visa from the AMF on March 19th, 2014 under the number 14-087, composed of the document de base filed with the AMF on March 3rd, 2014 under the number I. 14-005 and the note d'opération (including a summary of the prospectus), may be obtained free of charge at Genomic Vision's headquarters, Green Square - Bâtiment E, 80-84 rue des Meuniers, 92220 Bagneux, from the internet websites of Genomic Vision (www.genomicvision.com) and the AMF (www.amf-france.org).

Risk factors – Genomic Vision draws the public's attention to chapter 4, "Risk factors", of the document de base registered with the AMF, and to chapter 2 "Risk factors related to the Offering" of the note d'opération.

ABOUT GENOMIC VISION

A spinoff of the Institut Pasteur, Genomic Vision is a molecular diagnostics company specialized in developing diagnostic tests for genetic diseases and cancers. Using "molecular combing", an innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. Having benefited from the financial support of the Institut Pasteur, SGAM AI, Vesalius Biocapital and Quest Diagnostics, the Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHelix FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France.

ABOUT MOLECULAR COMBINING

DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if "combed", and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient's genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

Pour en savoir plus: <http://www.genomicvision.com>

CONTACT

Genomic Vision
Aaron Bensimon
Co-founder, President & CEO
Tel.: +33 1 49 08 07 50
investors@genomicvision.com

NewCap.
Investor Relations & Financial
Communications
Dušan Orešanský / Emmanuel Huynh
Tel.: +33 1 44 71 94 92
gv@newcap.fr

DISCLAIMER

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

In particular:

This press release does not constitute an offer to sell or any solicitation to purchase or subscribe for securities in the United States. The shares, or any other securities of GENOMIC VISION, may not be offered or sold in the United States unless they are registered under the U.S. Securities Act of 1933, as amended, or exempt from registration. The shares of GENOMIC VISION have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and GENOMIC VISION does not intend to make any public offer of its shares in the United States.

This press release is solely an advertisement and does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003, as amended, in particular, by Directive 2010/73/EC of the European Parliament and the Council of November 24th, 2010 and as implemented in each member State of the European Economic Area (the "Prospectus Directive"). With respect to the member States of the European Economic Area which have transposed the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to in this press release requiring a publication by GENOMIC VISION of a prospectus in any member State, other than France. As a result, the shares of GENOMIC VISION may not be offered or will not be offered in any member State other than France, except, pursuant to the exemptions described in article 3(2) of the Prospectus Directive, if they have been implemented by the relevant member State or in any other circumstances not requiring GENOMIC VISION to publish a prospectus as provided under article 3(2) of the Prospectus Directive and/or regulations applicable in such member State.

This press release is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This press release is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

The prospectus registered with the Autorité des Marchés Financiers contains forward-looking statements. No guarantee is given as to these forecasts being achieved, which are subject to risks, including those described in the prospectus, and to the development of economic conditions, the financial markets and the markets in which GENOMIC VISION operates.